aja1121 wrote:My husband is going on this trial at the suggestion of his oncologist. It will be a couple of months before husband can try Avastin (very small open wound from APR is almost healed) so this is kind of a can't hurt/might help scenario. 66% chance of getting Xilonix, 33% chance of placebo. Scan 8 weeks after trial starts, and they will pull him off if there's any progression. At that point, next step will be to try FOLFOX/Avastin or look at another clinical trial.
DH2Sleen wrote:While I don't have the pedigree that DK37 and Grouseman have, I can see some problems with this report.
First of all, this is a report from Europe and has no bearing on the US trial that is ongoing.
Second, it is somewhat misleading in the way it was reported. The actual endpoint of the study was not "overall survival" but rather "a predictor of overall survival" (which was quoted from the chairman of the study). After that paragraph, the reporter interpreted that statement to mean an increase in overall survival with reduced fatigue and pain and better appetite, but in fact, the study found no increase in overall survival and was not looking for it (according to another report: https://www.thestreet.com/story/1362832 ... utiny.html).
I'm no expert, but I think the jury is still out on this one.
Nik Colon wrote:DH2Sleen wrote:While I don't have the pedigree that DK37 and Grouseman have, I can see some problems with this report.
First of all, this is a report from Europe and has no bearing on the US trial that is ongoing.
Second, it is somewhat misleading in the way it was reported. The actual endpoint of the study was not "overall survival" but rather "a predictor of overall survival" (which was quoted from the chairman of the study). After that paragraph, the reporter interpreted that statement to mean an increase in overall survival with reduced fatigue and pain and better appetite, but in fact, the study found no increase in overall survival and was not looking for it (according to another report: https://www.thestreet.com/story/1362832 ... utiny.html).
I'm no expert, but I think the jury is still out on this one.
From the link you posted. This statement makes no sense at all to me, unless I am reading it wrong.....
Responding colon cancer patients -- Xilonix or placebo, doesn't matter -- lived an average of 11.5 months! That's way better than the non-responding patients, who lived only an average of 4.2 months, XBiotech said.
Huh???!!! Am I missing something?
Is placebo used different here? So the drug AND placebo are equal. Non responders? To both? Huh? What are the placebo people responding to?
midlifemom wrote:Nik Colon wrote:DH2Sleen wrote:While I don't have the pedigree that DK37 and Grouseman have, I can see some problems with this report.
First of all, this is a report from Europe and has no bearing on the US trial that is ongoing.
Second, it is somewhat misleading in the way it was reported. The actual endpoint of the study was not "overall survival" but rather "a predictor of overall survival" (which was quoted from the chairman of the study). After that paragraph, the reporter interpreted that statement to mean an increase in overall survival with reduced fatigue and pain and better appetite, but in fact, the study found no increase in overall survival and was not looking for it (according to another report: https://www.thestreet.com/story/1362832 ... utiny.html).
I'm no expert, but I think the jury is still out on this one.
From the link you posted. This statement makes no sense at all to me, unless I am reading it wrong.....
Responding colon cancer patients -- Xilonix or placebo, doesn't matter -- lived an average of 11.5 months! That's way better than the non-responding patients, who lived only an average of 4.2 months, XBiotech said.
Huh???!!! Am I missing something?
Is placebo used different here? So the drug AND placebo are equal. Non responders? To both? Huh? What are the placebo people responding to?
Nik,
Not sure if I understand your question or the study, BUTT my initial understanding of this drug xilonix was to improve well being - reduce fatigue, nausea, improve appetite and well being. I believe some initial findings did unexpectedly show improved overall survival. What I think this is saying is that while OS was not improved, QOL was improved during those final months.
aja1121 wrote:It took a couple of weeks to get all the details in order, but my husband started the trial today. The infusion is complete; now we wait for an hour and he gets labs repeated before going home. He said he feels sleepy and his face is a little flushed, but his stomach is fine (nausea and diarrhea reported by about 20% of patients receiving Xilonix in earlier phases of the trial).
Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”
Users browsing this forum: No registered users and 176 guests